Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Hinckley, A. F. et al. Lyme disease testing by large commercial laboratories in the United States. Clin. Infect. Dis. 59, 676–681 (2014).
Borchers, A. T., Keen, C. L., Huntley, A. C. & Gershwin, M. E. Lyme disease: a rigorous review of diagnostic criteria and treatment. J. Autoimmun. 57, 82–115 (2015).
Aguero-Rosenfeld, M. E. & Wormser, G. P. Lyme disease: diagnostic issues and controversies. Expert Rev. Mol. Diagn. 15, 1–4 (2015).
Smith, A. J., Oertle, J. & Prato, D. Chronic lyme disease: persistent clinical symptoms related to immune evasion, antibiotic resistance and various defense mechanisms of Borrelia burgdorferi. Open J. Med. Microbiol. 4, 252 (2014).
Marques, A. Chronic Lyme disease: a review. Infect. Dis. Clin. North Am. 22, 341–360 (2008).
Bockenstedt, L. K. & Radolf, J. D. Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it? Clin. Infect. Dis. 58, 946–948 (2014).
Feng, J. et al. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library. Emerg. Microbes Infect. 3, e49 (2014).
Bockenstedt, L. K., Gonzalez, D. G., Haberman, A. M. & Belperron, A. A. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J. Clin. Invest. 122, 2652 (2012).
Hodzic, E., Feng, S., Holden, K., Freet, K. J. & Barthold, S. W. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52, 1728–1736 (2008).
Diterich, I., Rauter, C., Kirschning, C. J. & Hartung, T. Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression. Infect. Immun. 71, 3979–3987 (2003).
Dorr, T., Vulic, M. & Lewis, K. Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia coli. PLoS Biol. 8, e1000317 (2010).
Sharma, B., Brown, A. V., Matluck, N. E., Hu, L. T. & Lewis, K. Borrelia burgdorferi, the causative agent of lyme disease, forms drug-tolerant persister cells. Antimicrob. Agents Chemother. 59, 4616–4624 (2015).
Liang, F. T. et al. Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses. Infect. Immun. 72, 5759–5767 (2004).
Coutte, L., Botkin, D. J., Gao, L. & Norris, S. J. Detailed analysis of sequence changes occurring during vlsE antigenic variation in the mouse model of Borrelia burgdorferi infection. PLoS Pathog. 5, e1000293 (2009).
Radolf, J. D., Caimano, M. J., Stevenson, B. & Hu, L. T. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat. Rev. Microbiol. 10, 87–99 (2012).
Sapi, E. et al. Evaluation of in vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect. Drug Resist. 4, 97–113 (2011).
Feng, J., Shi, W., Zhang, S. & Zhang, Y. Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection. Emerg. Microbes Infect. 4, e31 (2015).
Feng, J., Weitner, M., Shi, W., Zhang, S., Sullivan, D. & Zhang, Y. Identification of additional anti-persister activity against Borrelia burgdorferi from an FDA drug library. Antibiotics 4, 397 (2015).
Lefas, G. & Chaconas, G. High-throughput screening identifies three inhibitor classes of the telomere resolvase from the lyme disease spirochete. Antimicrob. Agents Chemother. 53, 4441–4449 (2009).
Cornell, K. A., Primus, S., Martinez, J. A. & Parveen, N. Assessment of methylthioadenosine/S-adenosylhomocysteine nucleosidases of Borrelia burgdorferi as targets for novel antimicrobials using a novel high-throughput method. J. Antimicrob. Chemother. 63, 1163–1172 (2009).
Wagh, D., Pothineni, V. R., Inayathullah, M., Liu, S., Kim, K.-M. & Rajadas, J. Borreliacidal activity of Borrelia metal transporter A (BmtA) binding small molecules by manganese transport inhibition. Drug Des. Dev. Ther. 9, 805 (2015).
Pothineni, V. R. et al. Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening. Drug Des. Dev. Ther. 10, 1307–1322 (2016).
Kraiczy, P. et al. In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 45, 2486–2494 (2001).
Beyer, D. & Pepper, K. The streptogramin antibiotics: update on their mechanism of action. Expert Opin. Investig. Drugs 7, 591–599 (1998).
Acknowledgements
This work was accomplished with a generous support from the Bay Area Lyme Foundation. We are indebted to Dr Robert Lane (UC Berkley, CA, USA) for his constant support, discussion and provision of valuable bacterial strains for the study. We also thank Jack, Christina West, Jonathan Locke and Elizabeth Hulmes for their generous support for this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on The Journal of Antibiotics website
Supplementary information
Rights and permissions
About this article
Cite this article
Pothineni, V., Wagh, D., Babar, M. et al. Screening of NCI-DTP library to identify new drug candidates for Borrelia burgdorferi. J Antibiot 70, 308–312 (2017). https://doi.org/10.1038/ja.2016.131
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2016.131
